Focus on the right trend and relax

Archive for May, 2010

SanDisk and the iPhone

During the last half year and especially the last month SanDisk’s stock has had a remarkable relative strength compared to the whole market.

sndk260510

This maker of flash memory is one beneficiary of the strong trend towards smart phones and tablet computers. Right now its chart has also the promising pattern of a restart in a longer trend.

However, there is a big caveat with this stock. As the long term chart reveals, SanDisk has a highly cyclical product, memory chips, which is probably the mother of all cycles. It remains to be seen whether this stock will be able to convert its cycling nature into a secularly trending growth monster, at least for some time.

sndk260510w


Stopped out of an imploding ETF

Yesterday’s spooky break down of the markets culminated in some stocks having losses of nearly 100%. The exchanges now try to “correct” this implosion after the matter of fact with a crude rule that cancels all trades with more than 60% movement in a time frame of 20 minutes. They seem to call this ad hoc rule the “Clearly Erroneous Ruling Policy”.

But were these trades clearly erroneous? Most of them were probably caused by stop and market sell orders that didn’t find buying counterparts. From an exchange-technical point of view this is business as usual – nothing erroneous. Viewing it from the flip side, the legal angle, most likely exchanges are completely within the law with their invention of ad hoc policies like this.

But does such a ruling make sense for traders and investors?

  • For traders who rely on a stop loss system, a monster drop like this may be demoralizing if they lose their position near the low.
  • Aggressive traders using margin may be put out of business. Their broker may liquidate their position at exactly the wrong time. Or they do it themselves with a market order that gets delayed under fast market conditions. Both likely profit from the trade cancellation.
  • Investors not knowing about a stop loss are mostly unaffected by temporary crashes like this.
  • Those professionals who think they can buy dirt cheap, may find themselves with one leg chopped off if their sale occurred outside of the arbitrary trade busting time frame.

Overall, I think, it indeed makes sense to protect the ordinary trader who tries to prohibit substantial losses with stop sell orders.

For visualization purposes let’s have a look at the weekly chart of URE, a real estate ETF. Yesterday it seems to have crashed by more than 90% in a few minutes before rebounding to a day loss of only 10%. One year ago it got devalued by roughly the same factor 10 during the financial crisis.

ure050510

Investors would have lost in half a year the same amount as traders in half an hour. But investors do this regularly, because stopping a position is nothing they have in their toolbox.

The conclusion for me is that, while yesterday the traders were worse off than investors, generally it is the other way round. In other words, it still pays off to use the stop loss technique.

Another conclusion may be that many ETFs seem not to have built real trust with regard to inherent value. The market apparently views them more as trading vehicles whose fundamental value is more or less unknown.

And the final conclusion for quoTraders is of course to use a system that concentrates on bigger stocks with real value and promising growth outlook, but doesn’t rely on fundamental analysis while the ship is slowly sinking.


Biotechnology may help people but kills traders

Among the things a quoTrader should never do, is trading stocks that depend on the FDA. Just look at this terrible chart of InterMune. Yesterday news came out that ITMN received a “complete” letter from the Food and Drug Administration, the stock got halted – especially nasty, namely intraday – and reopened with a loss of 75%.

All this after it made two days ago a restart in something that can only be called a violent trend. Of course it is also a suspicious trend, because of the double gap that essentially accounted for the whole move.

If you had shorted it some weeks ago, you could have incurred a loss of even 200%. Here we have another thing a quoTrader won’t do: Going short, at least not with single stocks likes this one.

itmn050510

The reason for the up and down is the same medicine and a “slight” change of opinions from officials about it. In this case it seems to be a law that requires studies and not only one study that show that a drug is overall a gain for patients. This prompted the FDA to demand a third phase III trial after external experts (an outside panel of the FDA) recommended an approval earlier.